KSKarl Andreas Schlegel

Karl Andreas Schlegel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karl Andreas Schlegel has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sinuslift - wann, wie und womit?

    by Christopher Prechtl, Karl Andreas Schlegel

    Die Implantologie ist eine zahnmedizinische Disziplin, die einen starken Wandel durchlebt hat. Anfangs handelte es sich bei diesem Fachgebiet um einen experimentellen Therapieansatz, um Zahnwurzeln zu ersetzen und Prothesen stabiler zu verankern, als dies auf konventionell-prothetischem Weg möglich war. Über die Jahrzehnte konnte sich die implantologische Rehabilitation von Patienten zu einem etablierten Therapiekonzept entwickeln, welches dem Behandler und dem Patienten hohe Erfolgsquoten in Aussicht stellt [38]. Dabei hat sich als Implantatform das enossale Schraubenimplantat als gängigstes Modell und Implantatdesign durchgesetzt. Für die Insertion von Implantaten ist immer ein qualitativ und quantitativ ausreichendes Knochenlager notwendig, welches der Verankerung des Implantats dient. Hier offenbaren sich in vielen Patientenfällen jedoch Probleme (Abb. [1]). Für die Insertion und die stabile Osseointegration enossaler Implantate – und natürlich auch, um ein ästhetisch akzeptables Ergebnis zu erreichen – ist in solchen Fällen eine Augmentation des Kieferknochens notwendig [32]. Im posterioren Oberkiefer besteht beim älteren Patienten häufig eine Alveolarkammatrophie in Kombination mit weit ausgedehnten Kieferhöhlen (Volumen beim Erwachsenen bis zu 12 cm3), was Restknochenhöhen von 1 mm in diesem Bereich zu keiner Seltenheit macht. Um Implantate stabil zu inserieren ist jedoch ein erheblich größeres Knochenangebot notwendig, was eine Augmentation erforderlich macht. In vielen Fällen ist dann eine Einlagerungsosteoplastik im Bereich des Kieferhöhlenbodens indiziert. Zusätzlich kann bei einer stark reduzierten Breite des Alveolarknochens eine Anlagerungsosteoplastik nötig sein. Auflagerungsosteoplastiken sind dagegen eher selten indiziert. Diese sind dann angezeigt, wenn die vertikale Kieferrelation in diesem Bereich eine prothetische Versorgung erschwert [7].

  • Open Access

    Bisphosphonate-associated osteonecrosis of the jaw is linked to suppressed TGFβ1-signaling and increased Galectin-3 expression: A histological study on biopsies

    by Falk Wehrhan, Peter Hyckel, Arndt Guentsch, Emeka Nkenke, Phillip Stockmann, Karl A Schlegel, Friedrich W Neukam, Kerstin Amann

    Bisphosphonate associated osteonecrosis of the jaw (BRONJ) implies an impairment in oral hard- and soft tissue repair. An understanding of the signal transduction alterations involved can inform therapeutic strategies. Transforming growth factor β1 (TGFβ1) is a critical regulator of tissue repair; galectin-3 mediates tissue differentiation and specifically modulates periodontopathic bacterial infection. The aim of this study was to compare the expression of TGFβ1-related signaling molecules and Galectin-3 in BRONJ-affected and healthy mucosal tissues. To discriminate between BRONJ-specific impairments in TGFβ1 signaling and secondary inflammatory changes, the results were compared to the expression of TGFβ1 and Galectin-3 in mucosal tissues with osteoradionecrosis.


  • Open Access

    Expression of Msx-1 is suppressed in bisphosphonate associated osteonecrosis related jaw tissue-etiopathology considerations respecting jaw developmental biology-related unique features

    by Falk Wehrhan, Peter Hyckel, Jutta Ries, Phillip Stockmann, Emeka Nkenke, Karl A Schlegel, Friedrich W Neukam, Kerstin Amann

    Bone-destructive disease treatments include bisphosphonates and antibodies against the osteoclast differentiator, RANKL (aRANKL); however, osteonecrosis of the jaw (ONJ) is a frequent side-effect. Current models fail to explain the restriction of bisphosphonate (BP)-related and denosumab (anti-RANKL antibody)-related ONJ to jaws. Msx-1 is exclusively expressed in craniofacial structures and pivotal to cranial neural crest (CNC)-derived periodontal tissue remodeling. We hypothesised that Msx-1 expression might be impaired in bisphosphonate-related ONJ. The study aim was to elucidate Msx-1 and RANKL-associated signal transduction (BMP-2/4, RANKL) in ONJ-altered and healthy periodontal tissue.


    • 4 April 2008
      • Vol. 28, 309-14

    The interleukin-10 (-1082A/G) polymorphism is strongly associated with increased risk for oral squamous cell carcinoma.

    by Eleftherios Vairaktaris, Christos Yapijakis, Zoe Serefoglou, Spyridoula Derka, Stavros Vassiliou, Emeka Nkenke, Antonis Vylliotis, Sofia Spyridonidou, Friedrich W Neukam, Karl A Schlegel, et al.

    Increased levels of interleukin-10 (IL-10) have been observed in patients with oral cancer, possibly as a result of suppression of the immune response. Based on this, the -1082A/G polymorphism, which influences IL-10 gene expression level, was investigated in regard to its possible association with risk for oral cancer. The polymorphism was examined in DNA samples of 144 patients with oral squamous cell carcinoma and 141 healthy controls of equivalent gender, age and ethnicity. The detected allele frequencies for the high expression G allele were significantly higher in patients compared to controls (34.7% versus 21.3%, respectively, p=0.0004), as well as in patients that were smokers but not those that were heavy alcohol consumers. This highly significant difference in G allele frequency was mainly due to the increase of AG heterozygotes in patients compared to controls (OR 3.05, 95% CI 1.84-5.05). These findings suggest that the high expression G allele of the -1082A/G polymorphism of the inflammation and angiogenesis-related IL-10 is strongly associated with increased risk for oral cancer.